Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Breast Neoplasms
/ drug therapy
Female
Fertility Preservation
/ methods
Humans
Infertility, Female
/ therapy
Letrozole
/ administration & dosage
Oocytes
/ drug effects
Ovulation Induction
/ methods
Retrospective Studies
Tamoxifen
/ administration & dosage
Young Adult
Breast cancer
Fertility preservation
Letrozole
Oocyte cryopreservation
Tamoxifen
Journal
Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
09
2020
accepted:
02
12
2020
pubmed:
8
1
2021
medline:
3
8
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
To assess the effects of letrozole or tamoxifen coadministration on fertility preservation treatment outcomes. Retrospective cohort study of 118 breast cancer patients undergoing fertility preservation treatment between 2008 and 2018. Patients who received letrozole (n = 36) or tamoxifen (n = 30) were compared to controls (n = 52) who underwent standard ovarian stimulation protocols. The primary outcome measures included the number of retrieved oocytes, mature oocytes (MII), fertilization, and top-quality embryo rates. The secondary outcome measures included duration of stimulation, gonadotropin dose and peak estradiol level. The number of oocytes retrieved, MII oocytes, fertilization rate, duration of stimulation, or gonadotropin dose were similar in the letrozole and tamoxifen groups, compared to controls. Top-quality embryo rate was lower in the tamoxifen group compared to controls (25% vs 39.4%, respectively, P = 0.034). The abnormal fertilization rate was higher in the letrozole group compared to controls (7.8% vs 3.60%, respectively, P = 0.015). A stepwise logistic regression analysis revealed that letrozole and peak estradiol were significantly associated with abnormal fertilization (OR 11.94; 95% CI 2.35-60.4, P = 0.003 for letrozole and OR 1.075; 95% CI 1.024-1.12, P = 0.004 per 100 unit change in estradiol). There may be a negative effect of letrozole or tamoxifen on fertilization and embryo quality, in fertility preservation cycles. Further studies are needed to confirm these findings.
Identifiants
pubmed: 33409757
doi: 10.1007/s10815-020-02030-y
pii: 10.1007/s10815-020-02030-y
pmc: PMC7910385
doi:
Substances chimiques
Tamoxifen
094ZI81Y45
Letrozole
7LKK855W8I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
743-750Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551 .
doi: 10.3322/caac.21551
pubmed: 30620402
pmcid: 30620402
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92. https://doi.org/10.1056/NEJMoa050518 .
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62. https://doi.org/10.3322/caac.21203 .
doi: 10.3322/caac.21203
pubmed: 24114568
Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–29. https://doi.org/10.1200/JCO.1996.14.5.1718 .
doi: 10.1200/JCO.1996.14.5.1718
pubmed: 8622093
Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992;166(3):788–93. https://doi.org/10.1016/0002-9378(92)91335-8 .
Zhao J, Liu J, Chen K, Li S, Wang Y, Yang Y, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113–28. https://doi.org/10.1007/s10549-014-2914-x .
Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, et al. Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2019;111(1):86–94. https://doi.org/10.1093/jnci/djy094 .
Kasum M, von Wolff M, Franulic D, Cehic E, Klepac-Pulanic T, Oreskovic S, et al. Fertility preservation options in breast cancer patients. Gynecol Endocrinol : the official journal of the International Society of Gynecological Endocrinology. 2015;31(11):846–51. https://doi.org/10.3109/09513590.2015.1081684 .
doi: 10.3109/09513590.2015.1081684
Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 Jul 1;36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914 .
Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA Jr, Bianchi-Micheli G, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol. 2020;31:674–96. https://doi.org/10.1016/j.annonc.2020.03.284 .
Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31:1664–78. https://doi.org/10.1016/j.annonc.2020.09.006 .
Pena JE, Chang PL, Chan LK, Zeitoun K, Thornton MH 2nd, Sauer MV. Supraphysiological estradiol levels do not affect oocyte and embryo quality in oocyte donation cycles. Hum Reprod. 2002;17(1):83–7. https://doi.org/10.1093/humrep/17.1.83 .
doi: 10.1093/humrep/17.1.83
pubmed: 11756366
Pittaway DE, Wentz AC. Evaluation of the exponential rise of serum estradiol concentrations in human menopausal gonadotropin-induced cycles. Fertil Steril. 1983;40(6):763–7. https://doi.org/10.1016/s0015-0282(16)47476-5 .
doi: 10.1016/s0015-0282(16)47476-5
pubmed: 6418575
Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves GK, Travis RC, et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol. 2013;14(10):1009–19. https://doi.org/10.1016/S1470-2045(13)70301-2 .
doi: 10.1016/S1470-2045(13)70301-2
Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270–82. https://doi.org/10.1056/NEJMra050776 .
doi: 10.1056/NEJMra050776
pubmed: 16421368
Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364–71. https://doi.org/10.1210/jc.2015-3878 .
doi: 10.1210/jc.2015-3878
pubmed: 26751194
pmcid: 4880171
Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–5. https://doi.org/10.1093/humrep/deg045 .
doi: 10.1093/humrep/deg045
pubmed: 12525446
Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53. https://doi.org/10.1200/JCO.2005.05.037 .
doi: 10.1200/JCO.2005.05.037
pubmed: 15824416
Klopper A, Hall M. New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J. 1971;1(5741):152–4. https://doi.org/10.1136/bmj.1.5741.152 .
doi: 10.1136/bmj.1.5741.152
pubmed: 5539422
pmcid: 1795152
Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339(8784):1–15.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88. https://doi.org/10.1093/jnci/90.18.1371 .
Prichard RS, Hill AD, Dijkstra B, McDermott EW, O'Higgins NJ. The prevention of breast cancer. Br J Surg. 2003;90(7):772–83. https://doi.org/10.1002/bjs.4218 .
doi: 10.1002/bjs.4218
pubmed: 12854100
Ekholm M, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Ryden L. Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (> 25 years) of the phase III SBII:2pre trial. J Clin Oncol. 2016;34(19):2232–8. https://doi.org/10.1200/JCO.2015.65.6272 .
doi: 10.1200/JCO.2015.65.6272
pubmed: 27161974
Santen RJ. Recent progress in development of aromatase inhibitors. J Steroid Biochem Mol Biol. 1990;37(6):1029–35.
doi: 10.1016/0960-0760(90)90461-S
Pfister CU, Martoni A, Zamagni C, Lelli G, De Braud F, Souppart C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos. 2001;22(5):191–7.
doi: 10.1002/bdd.273
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–9. https://doi.org/10.1200/JCO.2003.04.194 .
doi: 10.1200/JCO.2003.04.194
pubmed: 12775735
Breast International Group 1-98 Collaborative G, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57. https://doi.org/10.1056/NEJMoa052258 .
doi: 10.1056/NEJMoa052258
Casper RF, Mitwally MF. A historical perspective of aromatase inhibitors for ovulation induction. Fertil Steril. 2012;98(6):1352–5. https://doi.org/10.1016/j.fertnstert.2012.10.008 .
doi: 10.1016/j.fertnstert.2012.10.008
pubmed: 23200665
Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305–9. https://doi.org/10.1016/s0015-0282(00)01705-2 .
doi: 10.1016/s0015-0282(00)01705-2
pubmed: 11172831
Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril. 2012;97(4):930–4. https://doi.org/10.1016/j.fertnstert.2012.01.093 .
doi: 10.1016/j.fertnstert.2012.01.093
pubmed: 22283969
Checa Vizcaino MA, Corchado AR, Cuadri ME, Comadran MG, Brassesco M, Carreras R. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod BioMed Online. 2012;24(6):606–10. https://doi.org/10.1016/j.rbmo.2012.02.020 .
doi: 10.1016/j.rbmo.2012.02.020
pubmed: 22503276
Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol : the official journal of the International Society of Gynecological Endocrinology. 2013;29(11):993–6. https://doi.org/10.3109/09513590.2013.819083 .
doi: 10.3109/09513590.2013.819083
Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril. 2014;102(2):488–95 e3. https://doi.org/10.1016/j.fertnstert.2014.05.017 .
Practice Committee of the American Society for Reproductive Medicine. Electronic address aao. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–33. https://doi.org/10.1016/j.fertnstert.2019.09.013 .
doi: 10.1016/j.fertnstert.2019.09.013
Practice Committees of the American Society for Reproductive M, Society for Assisted Reproductive T. Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion. Fertil Steril. 2012;98(6):1395–9. https://doi.org/10.1016/j.fertnstert.2012.08.026 .
doi: 10.1016/j.fertnstert.2012.08.026
Racowsky C, Vernon M, Mayer J, Ball GD, Behr B, Pomeroy KO, et al. Standardization of grading embryo morphology. Fertil Steril. 2010;94(3):1152–3. https://doi.org/10.1016/j.fertnstert.2010.05.042 .
doi: 10.1016/j.fertnstert.2010.05.042
pubmed: 20580357
Racowsky C, Ohno-Machado L, Kim J, Biggers JD. Is there an advantage in scoring early embryos on more than one day? Hum Reprod. 2009;24(9):2104–13. https://doi.org/10.1093/humrep/dep198 .
doi: 10.1093/humrep/dep198
pubmed: 19493872
pmcid: 2727402
Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033–45. https://doi.org/10.1093/humrep/dex027 .
Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod BioMed Online. 2010;20(6):783–8. https://doi.org/10.1016/j.rbmo.2010.03.004 .
doi: 10.1016/j.rbmo.2010.03.004
pubmed: 20382080
pmcid: 3557820
Ben-Haroush A, Wertheimer A, Klochendler E, Sapir O, Shufaro Y, Oron G. Effect of letrozole added to gonadotropins in controlled ovarian stimulation protocols on the yield and maturity of retrieved oocytes. Gynecol Endocrinol: the official journal of the International Society of Gynecological Endocrinology. 2019;35(4):324–7. https://doi.org/10.1080/09513590.2018.1534950 .
doi: 10.1080/09513590.2018.1534950
Cobo A, Garcia-Velasco J, Domingo J, Pellicer A, Remohi J. Elective and Onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222–31. https://doi.org/10.1093/humrep/dey321 .
doi: 10.1093/humrep/dey321
pubmed: 30383235
Bonardi B, Massarotti C, Bruzzone M, Goldrat O, Mangili G, Anserini P, et al. Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: a systematic review and meta-analysis. Front Oncol. 2020;10:574669. https://doi.org/10.3389/fonc.2020.574669 .
Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril. 2013;100(6):1681–5 e1. https://doi.org/10.1016/j.fertnstert.2013.08.030 .
doi: 10.1016/j.fertnstert.2013.08.030
pubmed: 24055050
pmcid: 3888552
Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21. https://doi.org/10.1126/scitranslmed.3004925 .
doi: 10.1126/scitranslmed.3004925
pubmed: 23408054
pmcid: 5130338
Phillips KA, Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, et al. Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–32. https://doi.org/10.1093/humrep/dew044 .
Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013;119(9):1652–9. https://doi.org/10.1002/cncr.27952 .
Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril. 2013;99(6):1724–8. https://doi.org/10.1016/j.fertnstert.2013.01.109 .
Son KA, Lee DY, Choi D. Association of BRCA mutations and anti-Mullerian hormone level in young breast cancer patients. Front Endocrinol (Lausanne). 2019;10:235. https://doi.org/10.3389/fendo.2019.00235 .
doi: 10.3389/fendo.2019.00235
Porcu E, Cillo GM, Cipriani L, Sacilotto F, Notarangelo L, Damiano G, et al. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer. J Assist Reprod Genet. 2020;37(3):709–15. https://doi.org/10.1007/s10815-019-01658-9 .
Lambertini M, Goldrat O, Toss A, Azim HA Jr, Peccatori FA, Ignatiadis M, et al. Fertility and pregnancy issues in BRCA-mutated breast cancer patients. Cancer Treat Rev. 2017;59:61–70. https://doi.org/10.1016/j.ctrv.2017.07.001 .
Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2018;33(2):181–7. https://doi.org/10.1093/humrep/dex356 .
Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, et al. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril. 2015;104(5):1162–7. https://doi.org/10.1016/j.fertnstert.2015.07.1162 .
Gunnala V, Fields J, Irani M, D’Angelo D, Xu K, Schattman G, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2019;111(2):363–71. https://doi.org/10.1016/j.fertnstert.2018.10.014 .
doi: 10.1016/j.fertnstert.2018.10.014
pubmed: 30527950
Moor RM, Polge C, Willadsen SM. Effect of follicular steroids on the maturation and fertilization of mammalian oocytes. J Embryol Exp Morphol. 1980;56:319-335.
Welsh TH Jr, Jia XC, Jones PB, Zhuang LZ, Hsueh AJ. Disparate effects of triphenylethylene antiestrogens on estrogen and progestin biosyntheses by cultured rat granulosa cells. Endocrinology. 1984;115(4):1275–82. https://doi.org/10.1210/endo-115-4-1275.
Knecht M, Tsai-Morris CH, Catt KJ. Estrogen dependence of luteinizing hormone receptor expression in cultured rat granulosa cells. Inhibition of granulosa cell development by the antiestrogens tamoxifen and keoxifene. Endocrinology. 1985;116(5):1771–7. https://doi.org/10.1210/endo-116-5-1771.
Ortega I, Sokalska A, Villanueva JA, Cress AB, Wong DH, Stener-Victorin E, et al. Letrozole increases ovarian growth and Cyp17a1 gene expression in the rat ovary. Fertil Steril. 2013;99(3):889–96. https://doi.org/10.1016/j.fertnstert.2012.11.006.
Lossl K, Andersen AN, Loft A, Freiesleben NL, Bangsboll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod. 2006;21(10):2593–600. https://doi.org/10.1093/humrep/del221.
Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsboll S, Andersen AN. Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial. Hum Reprod. 2008;23(8):1820–9. https://doi.org/10.1093/humrep/den131.